RESULTS: The incidence of major bleeding among 4005 Medicare beneficiaries who underwent an incident surgery was 4.7%. Patients experiencing major bleeding had longer hospital lengths of stay (11.5 vs. 9.8 days, P < 0.01), longer ICU lengths of stay (10 vs. 7.7 days, P < 0.01), were more likely to die in the hospital (OR = 1.95, P < 0.01), and were responsible for significantly higher charges (+$18,512, P < 0.01) and reimbursements (+$2642, P < 0.01). Over two years of follow-up, patients with major bleeding were more likely to experience renal failure (OR = 1.40, P = 0.06), were more likely to die (P < 0.01), and incurred higher medical care costs (P < 0.05). CONCLUSION: Patients who experienced major bleeding during CABG requiring CPB tended to have poorer immediate and longer-term outcomes. Results suggest that interventions to prevent major bleeding during cardiac surgery may diminish or prevent these negative clinical and economic outcomes.

CV4

CAN TWO A’S RESULT IN A FAILURE?: EFFECT OF ASPIRIN ON THE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS
Shah DH, Parikh NM, Kamble PS, Chen H, Johnson M
University of Houston, Houston, TX, USA

OBJECTIVE: Aspirin use may negatively interact with the effect of ACE inhibitors in treating heart failure. Hence, we sought to determine whether aspirin increases the risk of heart failure hospitalizations in non-elderly CHF patients on ACE Inhibitors.

METHODS: A retrospective analysis of the 2001 Georgia Medicaid claims data was performed. Patients between 18–64 years of age who received a diagnosis of CHF (ICD-9 CM = 428.XX) and filled at least one prescription for ACE Inhibitors between January 1, 2001 and June 30, 2001 were included in the study. Among these patients, those receiving aspirin were classified as the exposed group and patients not receiving aspirin were classified as the unexposed group. Hospitalization due to heart failure was assessed between July 1, 2001 and December 31, 2001. Multi-variable logistic regression provided adjusted estimates of the aspirin effect, with nonusers as the reference group, after controlling for demographic factors, co-morbidities and co-medications.

RESULTS: One thousand four hundred fourteen patients were identified. The total number of aspirin users was 178 (12.58%). Average age was 51.36 years and most patients were females (66.5%). Also, most of the selected patients were African Americans (57.1%). The unadjusted odds ratio for the aspirin effect, with nonusers as the reference group, was 1.798 (95% CI 1.097–2.896) and the adjusted odds ratio was 1.782 (95% CI 1.074–3.009).

CONCLUSION: Aspirin use was associated with a greater risk of hospitalization due to heart failure in patients taking ACE Inhibitors.

DB2

COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO
Arreola-Ornelas H¹, Dorantes-Aguilar J¹, García-Mollinedo MDL², Rosado-Buzzo AA², Mouëd-Quevedo J¹, Davila-Loaiza G²
¹Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, ²Links & Links S.A. de C.V, Mexico City, Mexico

OBJECTIVE: Neuropathic pain is a chronic condition that causes functional impairment in many areas of life and it occurs frequently with diabetes. The aim of this study was to analyze the cost-effectiveness of different treatments in managing diabetic peripheral neuropathy from the health care payer’s perspective.

METHODS: A four-state stochastic Markov model was performed to estimate costs and effectiveness. The Markov model includes several stages related to functional disability (mild-pain, moderate-pain, severe-pain and death). Effectiveness was assumed as the percentage of patients with no or mild pain (pain score <4) at the end of the follow-up period (one-year). Transition probabilities were taken from national and international published literature. Comparators used in the assessment were carbamazepine (200–600 mg/day), amitriptyline (100–150 mg/day), gabapentin (2400–3600 mg/day) and pregabalin (300–600 mg/day). Resource use and costs were obtained from hospital records (n = 1000) from the Social Security Mexican Institute (IMSS) and official institutional databases. Costs include emergency, outpatient and inpatient services, drugs, procedures, etc. The model was calibrated. Probabilistic sensitivity analyses were performed employing bootstrapping techniques and acceptability curves were constructed.

RESULTS: The highest percentage of patients
with no or mild pain during the follow-up period was obtained by pregabalin (59.6%; CI95% 59.0%–60.2%); followed by gabapentin (49.2%; CI95% 48.7%–49.7%); amitrptyline (47.6%; CI95% 47.1%–48.1%) and carbamazepine (34.4%; CI95% 34.1%–34.8%). The annual expected mean costs per patient were US$3001.4 (CI95% US$2956.4–US$3046.3); US$4,707.7 (CI95% US$4689.9–US$4723.6); US$2814.4 (CI95% US$2783.4–US$2845.5) and US$3701.9 (CI95% US$3687.2–US$3716.6); respectively following the order above. The ICER's of vs. carabamazepine (baseline), gabapentin and amitrptyline were -US$700.5 (CI95% -US$670.4:-US$730.7), -US$1706.4 (CI95% -US$1677.3:-US$1733.4) and US$186.9 (CI95% US$173.1–US$200.8); respectively. Using acceptability curves (WTP US$5000–US$50,000), pregabalin showed a probability between 90–99% to be the treatment most cost-effective. CONCLUSION: In Mexico, pregabalin showed to be a cost-saving therapy when is compared with carabamazepine and gabapentin; and cost-effective vs. amitrptyline in the management of neuropathic pain.

**DB3**

**REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE**

Misurki D1, Schroeder B2, Wade R3, Quimbo R3, Nielsen L1, Fabunmi R2, Winde M4

1 Eli Lilly and Company, Indianapolis, IN, USA; 2 Amylin Pharmaceuticals, Inc. San Diego, CA, USA; 3 HealthCore, Inc, Wilmington, DE, USA

OBJECTIVE: The primary aim of type 2 diabetes (T2D) therapy is helping patients achieve glycemic goals (A1C < 7%) as recommended by the ADA. In the recent randomized controlled trials 4-T and INITIATE, patients treated with basal insulin alone achieved goal 28% and 40% of the time, respectively, despite progressive insulin titration. In this retrospective cohort study using a large, US commercial health plan claims database, we describe the clinical effectiveness of newly-prescribed basal insulin glargine (IG) in insulin-naive patients. METHODS: A total of 13,154 insulin-naive (not prescribed insulin in previous 6 mo) patients were identified with a new prescription claim for IG between January 1, 2004 and June 30, 2006, n = 6 mo of pre-index eligibility (first claim index date), ≥12 mo of post-index eligibility, and ≥18 y old. RESULTS: From this cohort, 7730 (59%) patients had no other insulin claims other than IG in the entire post-index period. All patients with baseline (100 d pre-index) and post-index (60–365 d) A1C data available and baseline A1C≥7.0% were analyzed (n = 313; mean baseline A1C (±SD) = 9.8 ± 2.1%). Mean (±SD) age was 52 ± 8 y (41% female; 3% ≥65 y). In this cohort of patients who did not add any additional insulin (n = 313), 27% achieved A1C < 7% in the post-index period (mean [min,max] time index to post-index A1C = 238 d [63,365]). Mean (±SD) post-index A1C was 8.2 ± 1.9%. CONCLUSION: In this real-world analysis of patients initiated on IG, the percentage of patients achieving A1C < 7.0% and mean post-index A1C indicate that most patients do not achieve recommended glycemic targets—results which mirror controlled clinical studies. In addition, more than half of patients initiating IG did not supplement with additional insulin therapy over the course of the first year of therapy, despite not reaching glycemic goals. Because the contribution of post-prandial glucose to A1C increases as A1C approaches goal, agents targeting fasting glucose alone, like IG, may be insufficient in helping patients with T2D achieve glycemic goals.

**DB4**

**RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLy CONTROLLED BY METFORMIN MONOTHERAPY**

He J, Nesbunan C

Johnson & Johnson Pharmaceutical Services LLC, Rantann, NJ; USA

OBJECTIVE: The American Diabetes Association (ADA) recommends metformin as first line treatment for T2DM. As diabetes is a progressive disease, patients will ultimately need additional therapies to reach glycemic goals. Little information has been published that describes what happens to patients not optimally controlled on metformin monotherapy in the real world. We analyzed monitoring, treatments and outcomes for such patients using the PHARMetrics® linked laboratory database. METHODS: An algorithm based on ICD-9 codes and laboratory test values identified 1901 T2DM patients who failed metformin monotherapy between 2000 and 2006. The index date was defined as the first Hba1c test greater than the ADA recommended goal of 7%, after at least 6 months metformin monotherapy. The pre-period was defined as two years prior to the index date. The follow-up period was defined as 12 months after the index date. Other laboratory test values were obtained during a +/-30-day window of the index date. Micro- and macrovascular diabetes-related complications were identified using ICD-9 codes during the pre-period. Subsequent glucose control and first therapy change in the 3 to 12 months of the follow-up period were also analyzed. RESULTS: A total of 48.5% of the sample was male. Mean age was 57.9 (±11). The prevalence of diabetic-related complications were as follows: retinopathy (12.64%); neuropathy (12.13%); nephropathy (2.67%); myocardial infarction (1.31%); stroke (2.82%) and ischemic heart disease (12.99%). In the follow-up period, 76.5% of patients had an Hba1c test and only 24.7% were at goal. Only 33% changed therapy: 19% added on sulfonylureas; 5% switched to a fixed-dose combination product and 4% added or switched to thiazolidinedione. Overall, the average time from failure until therapy change was 256.0 days (±73.1). CONCLUSION: These results indicate considerable unmet medical need in treating T2DM. Glycemic control would have likely been better with additional pharmaceutical utilization.

**DRUG USE RESEARCH I**

**DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION: ANALYSIS OF UNITED STATES NATIONAL DATA 2000–2005**

Karve S, Levine D, Balkrishnan R

The Ohio State University, Columbus, OH; USA

OBJECTIVE: To assess age, racial, and regional differences in utilization of physician, hospital outpatient and emergency department services related to stroke over the past six years. METHODS: This study was a retrospective analysis of the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) from 2000 to 2005. Ischemic stroke related visits in persons aged ≥45 years were identified using diagnosis codes (ICD 9 CM) 433.1x, 434.xx, and 436.xx. Visits per/1000 persons were calculated using United States population estimates. With logistic regression, we adjusted associations between stroke-related visits and age, race, and region (Northeast, Midwest, West, and South), for sex, stroke risk factors, insurance type, and survey year. RESULTS: From 2000 to 2005, stroke-related ambulatory care visits increased significantly from 8.3/1000 persons to 16.1/1000 persons (P Trend =<0.0001) representing a 195% rise in stroke...